References

1. 1.
   SUNG H， FERLAY J， SIEGEL R L， et al. Global cancer statistics 2020： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin， 2021，71（3）：209-249.
2. 2.
   KESSLER D A， AUSTIN R H， LEVINE H. Resistance to chemotherapy： Patient variability and cellular heterogeneity［J］. Cancer Res， 2014，74（17）：4663-4670.
3. 3.
   QI F， ZHAO L， ZHOU A， et al. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer［J］. Biosci Trends， 2015，9（1）：16-34.
4. 4.
   ZHOU J， ZHOU T， JIANG M， et al. Research progress on synergistic anti-tumor mechanisms of compounds in traditional Chinese medicine［J］. J Tradit Chin Med， 2014，34（1）：100-105.
5. 5.
   ZHANG F， XU C L， QIU Z. Advances and prospect in reversing multidrug resistance of tumor cells by Chinese materia medica［J］. Chin J Exp Tradit Med Form， 2013， 19（24）：342-348.
6. 6.
   ZHU Y Z， ZHANG G B， ZHU G F. Research progress in mechanism of anti-tumor effects of Chinese medicinal formula［J］. Chin J Exp Tradit Med Form， 2017，23（16）：227-234.
7. 7.
   DU Q， HU B， SHEN K P. Compatibility of Chinese anti-cancer herb［J］. Chin J Exp Tradit Med Form， 2010，16（13）：232-235.
8. 8.
   WEI Y L， WANG Z G. Theoretical research on compatibility of traditional Chinese medicines［J］. World J Tradit Chin Med， 2013，8（5）：509-511.
9. 9.
   HAN P. Analysis on assistant medication theory of professor Wang Xin-lu［J］. China Arch Tradit Chin Med， 2010，28（4）：701-702.
10. 10.
    TONG X L. State target medicine： The future development of Chinese medicine［J］. Chin J Integr Tradit West Med， 2021，41（1）：16-18.
11. 11.
    CHEN Y， ZHOU C， GE Z， et al. Composition and potential anticancer activities of essential oils obtained from myrrh and frankincense［J］. Oncol Lett， 2013，6（4）：1140-1146.
12. 12.
    LIU Y， CAO H F， ZHAO H， et al. Study on the method of invigorating and detoxicating in the treatment of tumor［J］. China J Basic Med Tradit Chin Med， 2023，29（1）：164-168.
13. 13.
    DU F， YU M X， HU B F. Research progress on clinical application and mechanism of Chinese medicine pair of Sparganii Rhizoma-Curcumae Rhizoma against tumor［J］. China Med Hera， 2023，20（2）：39-42.
14. 14.
    HUANG X， QIAN J， LI L， et al. Curcumol improves cisplatin sensitivity of human gastric cancer cells through inhibiting PI3K/Akt pathway［J］. Drug Dev Res， 2020，81（8）：1019-1025.
15. 15.
    DING Y， ZHUANG S， LI Y， et al. Hypoxia-induced HIF1α dependent COX2 promotes ovarian cancer progress［J］. J Bioenerg Biomembr， 2021，53（4）：441-448.
16. 16.
    SUN S R， YUAN C C， CHENG Z Q. The application of pill combined with elimination and supplementation in the treatment of malignant tumors［J］. Mod J Integr Tradit Chin West Med， 2022，31（16）：2333-2336.
17. 17.
    LI Y. Analysis and mechanism analysis of prescription drugs of traditional Chinese medicine in the treatment of pancreatic cancer［D］. Shenyang： Liaoning University of Traditional Chinese Medicine，2023.
18. 18.
    SUN R， GU J， CHANG X， et al. Metabonomics study on orthotopic transplantion mice model of colon cancer treated with Astragalus membranaceus-Curcuma wenyujin in different proportions via UPLC-Q-TOF/MS［J］. J Pharm Biomed Anal， 2021，193：113708.
19. 19.
    GU J F， SUN R L， LIU F Y， et al. Effect of Astragali Radix-Curcumae Rhizoma on SDF-1/CXCR4/NF-κB signaling pathway of orthotopic transplantation model of colon cancer in mice［J］. Chin J Exp Tradit Med Form， 2021，27（21）：63-72.
20. 20.
    WANG X H， XU D Q， HUANG L， et al. Research progress on compatibility mechanism of Coptidis Rhizoma-Euodiae Fructus ：A review［J］. Chin J Exp Tradit Med Form， 2022，28（3）：266-274.
21. 21.
    PEI X H， FANG Y Y. Combined effect of arsenic trioxide and tetrandrine on MCF-7 cell［J］. J Nanjing Univ Tradit Chin Med， 2009，25（2）：114-117.
22. 22.
    DENG L J， DONG Y， LIU L J， et al. Clinical research progress of Qinghuang powder in the treatment of myeloid tumors［J］. Intern Med J Pract Tradit Chin Med Sci， 2024，38（4）：30-33.
23. 23.
    ZHANG X， CHEN H， HUANG X， et al. Single-cell transcriptomics profiling the compatibility mechanism of As（2）O（3）-indigo naturalis formula based on bone marrow stroma cells［J］. Biomed Pharmacother， 2022，151：113182.
24. 24.
    XIA L. Study on mechanism of Pinellia and Ginger Synergistic anti proliferation and pro-apoptosis of ovarian cancer［D］. Jinan ： Shandong University of Traditional Chinese Medicine， 2022.
25. 25.
    CHAO LQ， WANG F.Analysis of the application of the "eighteen anti" compatible formulas of the Jing Fang［J］. Lishizhen Med Mater Med Res， 2022，33（2）：441-443.
26. 26.
    GAO X S， CHEN F X， LIU LX ， et al. The new meaning of the eighteen antis of traditional Chinese medicine—obstruction of treatment［J］. China J Chin Mater Med， 1992（12）：754-756.
27. 27.
    GU K X， YANG G Y. Examples of drug pair of negative effect inducing and toxicity restraint in clinical applications of tumors［J］. Jiangsu J Tradit Chin Med， 1998（3）：36-38.
28. 28.
    YANG G B， LIU Y F. Drug pair of negative effect inducing and toxicity restraint in the treatment of malignant tumors has been experienced［J］. Tradit Chin Med J ， 2014，13（6）：32-33.
29. 29.
    LIU Y R， HAO L，WANG T T， et al. Effect of compatibility of vinegar-processed Euphorbia Kansui and Radix Glycyrrhizae Preparata on cytochrome oxidase gene and protein expression in cancerous ascites model rats［J］. Tradit Chin Drug Res Clin Pharmacol， 2021，32（11）：1640-1647.
30. 30.
    LU S Y， TANG C Y， CUI S K， et al. A famous Chinese medicine practitioner ZHANG Xijian's experience in treating lung cancer with seaweed-licorice medicine［J］. Asia-Pacific Tradit Med， 2021，17（7）：109-111.
31. 31.
    YU Y， LI K， SUN G Z. Experience of Professor SUN Guizhi treating tumors with activating blood and resolving stasis［J］. Liaoning J Tradit Chin Med， 2014，41（6）：1109-1111.
32. 32.
    YAN H F. YU Guiqing's tumor drug pair and drug group research［J］. J Tradit Chin Med Lit， 2003（4）：37-39.
33. 33.
    LI J S， ZHENG T T， JIN J J， et al. XU Bin's experience in the treatment of primary liver cancer is commonly used［J］. New Chin Med， 2018，50（2）：185-187.
34. 34.
    JIANG S P. Professor YANG Xinzhong commonly used drugs for the treatment of tumors［J］. Jilin J Chin Med， 2010，30（4）：289-291.
35. 35.
    ZHOU B S， CHEN T， YANG X H， et al. Experience introduction of commonly-used couplet medicines in treating cancer by SHU Qijin［J］. New Chin Med， 2020，52（1）：194-197.
36. 36.
    WANG H Y， XIA L， QI Y F. Experience by professor QI Yuanfu in treating tumor with heat-clearing and detoxification paired medicinals［J］. Shandong J Tradit Chin Med， 2023，42（4）：376-380.
37. 37.
    JIAO M H， QI Y F. Professor QI Yuanfu experience of using drug pair of clearing heat-toxin in the treatment of lung cancer［J］. Yunnan J Tradit Chin Med Mater Med，2020，41（11）：9-12.
38. 38.
    ZHEN L D， GUO Y. Exploration on herb pairs frequently-used by GUO Yong in therapy of cancer diseases［J］. J Liaoning Univ Tradit Chin Med， 2016，18（5）：131-133.
39. 39.
    DING D W， ZHANG Y H. Professor ZHANG Yonghong extracts commonly used drugs for the treatment of lung cancer［J］. Lishizhen Med Mater Med Res， 2014，25（12）：3046-3047.
40. 40.
    WANG M M. Director ZHANG Peitong's treatment based on data mining A study on the analysis of prognostic factors in patients with membranous adenocarcinoma［D］. Beijing ： Beijing University of Chinese Medicine， 2017.
41. 41.
    LIAO S H. Study on clinical prescriptions and drug compatibility features of Fujian and Taiwan famous doctors of traditional Chinese medicine -Aoshi CHEN professor ［D］. Fuzhou： Fujian University of Traditional Chinese Medicine， 2017.
42. 42.
    WU N， NING Y C， TANG M， et al. YANG Yufei's experience in the treatment of ovarian cancer based on the theory of "emotional pathogenesis"［J］. China J Basic Med Tradit Chin Med， 2022，28（12）：2050-2052.
43. 43.
    LU D D， WANG J， LIU H， et al. WANG Pei's experience in the treatment of tumors with mineral drugs［J］. Jiangsu J Tradit Chin Med， 2023，55（10）：16-20.
44. 44.
    SUN D D， WEI X M， ZHU M L， et al. WU Mianhua's experience on the treatment of malignant tumors［J］. China J Tradit Chin Med Pharm， 2024，39（4）：1816-1819.
45. 45.
    ZHANG B， ZHANG L. GUO Zhixiong used the experience of formulae and drug pair to treat thyroid cancer［J］. Chin Commun Doct， 2012，14（1）：206.
46. 46.
    YW Q， LIU X Q， WANG D X， et al. WANG Xinlu's experience in using Hongjingtian（Radix et Rhizoma Rhodiolae Crenulatae） in clinical practice［J］. J Tradit Chin Med， 2024，65（9）：887-891.
47. 47.
    LI Y C. Research on the clinical experience of Professor WANG Xixing in the treatment of cervical cancer based on data mining［D］. Taiyuan ： Shanxi Provincial Institute of TCM， 2021.
48. 48.
    YUAN Q， ZHANG G D， HUANG K. Professor WEI Zixiao's experience in using paired medicine of Vespae Nidus［J］. Tianjin J Tradit Chin Med， 2022，39（3）：291-294.
49. 49.
    ZHAO J M， XU T， WANG N， et al. Discussion of the compatibility laws of triangle medicine based on Shushu ''three''［J］. China J Tradit Chin Med Pharm， 2021，36（9）：5448-5450.
50. 50.
    WANG X， ZAHNG Y W. Application of angle drugs in primary liver cancer［J］. Chin J Integr Tradit West Med Digest， 2022，30（2）：151-154.
51. 51.
    XU X H， LI T， WANG Y T， et al. Research progress in Persicae Semen［J］. Chin Tradit Herb Drug， 2015，46（17）：2649-2655.
52. 52.
    GE G F， YU C H， WU X F. Anti-proliferative effects of ethanol extract from Eupolyphaga sinesis Walker in vitro［J］. China J Tradit Chin Med Pharm， 2013，28（3）：826-828.
53. 53.
    SU J， YAN Y， QU J， et al. Emodin induces apoptosis of lung cancer cells through ER stress and the TRIB3/NF-κB pathway［J］. Oncol Rep， 2017，37（3）：1565-1572.
54. 54.
    ZHANG X Z. Analysis of the law and mechanism of classic formula and period formula for the treatment of cancer pain［D］. Shenyang ： Liaoning University of Traditional Chinese Medicine，2021.
55. 55.
    ZHAO H， LI Y， WANG Y， et al. Antitumor and immunostimulatory activity of a polysaccharide-protein complex from Scolopendra subspinipes mutilans L. Koch in tumor-bearing mice［J］. Food Chem Toxicol， 2012，50（8）：2648-2655.
56. 56.
    SHI L， ZHANG T X， DU C Y， et al. Research progress on chemical constituents， pharmacological effects and clinical applications of scorpio［J］. J Liaoning Univ Tradit Chin Med， 2015，17（4）：89-91.
57. 57.
    WANG YL， NING Y， DIN Y. Research progress on chemical constituents and pharmacological action of earthworm［J］. Inf Tradit Chin Med， 2022，39（12）：86-89.
58. 58.
    ZHANG Z， ZHANG P T， ZAHNG R Q. Professor ZHANG Peitong's experience in the treatment of small cell lung cancer with triangular medicines［J］. Jilin J Chin Med， 2023，43（11）：1280-1284.
59. 59.
    SHOU F Y， GAO Y， WAN H Y， et al. Summary of the treatment of colorectal cancer with horn medicine by famous veteran traditional Chinese medicine practitioners［J］. Clin J Tradit Chin Med， 2023，35（9）：1709-1713.
60. 60.
    ZHANG L. Professor ZHOU Zhongying's experience in treating lung cancer with triplet herbs［J］. Shanghai J Tradit Chin Med， 2013，47（11）：1-2.
61. 61.
    DEN X G， YUAN B， FAN H Q. LIU Lifang's experience in the treatment of breast cancer using angle drugs［J］. Global Tradit Chin Med， 2024，17（1）：78-80.
62. 62.
    LAI Y X， CUI J W， YAN H， et al. Analysis of JIANG Liangduo's commonly used angle drugs in the treatment of lung cancer［J］. Global Tradit Chin Med， 2021，14（8）：1465-1468.
63. 63.
    LIU L T， LIU Q， FANG Z J. XU Hefen's example of the use of angle drugs for the treatment of tumors［J］. Jiangsu J Tradit Chin Med， 2016，48（12）：9-10.
64. 64.
    YANG T， CAI Y， YUAN C Y， et al. CHEN Weijian is based on "group treatment" and commonly used angle drugs for lung cancer［J］. Zhejiang J Integr Tradit Chin West Med， 2023，33（11）：1065-1067.
65. 65.
    ZHANG R Q， ZHAO W H， LEI G P， et al. Professor LEI Genping's experience in the treatment of esophageal cancer with pair medicine and horn medicine［J］. Chin Med Rep， 2022，19（2）：130-133.
66. 66.
    HAO S L， NING B B， ZHANG X W. WANG Xixing's experience of using angle drugs in the treatment of brain tumors［J］. China Naturopathy， 2020，28（11）：37-40.
67. 67.
    FAN T B， YANG Z X. Experience of utilization of tri-herb combination of Scorpio， Pheretima and Bombyx batryticatus prescribed by professor GUO Ziguang in treating cancer pain［J］. J Oncol Chin Med， 2019（1）：4-7.
68. 68.
    ZHUO W Q， DING C X， FANG Z J， et al. ZHANG Yonghong's experince of using angle drugs in the treatment of thoracic and abdominal tumors［J］. Jiangxi J Tradit Chin Med， 2019，50（1）：25-26.
69. 69.
    WANG Q Q， LI X G， ZHOU C P， et al. Master of traditional Chinese medicine QIU Peiran's experience in tumor treatment［J］. Tradit Chin Med J， 2016，15（6）：27-29.
70. 70.
    ZHOU Z Y， CHENG H B， ZHOU X P， et al. On tumor differentiation and treatment by TCM［J］. J Nanjing Univ Tradit Chin Med， 2014，30（2）：101-104.
71. 71.
    CHENG H B， LI L， SHEN W X， et al. System construction for the syndrome differentiation and treatment of cancer toxin［J］. J Nanjing Univ Tradit Chin Med， 2022，38（7）：559-564.
72. 72.
    LI L， CHENG H B， YE F， et al. Analysis of masters of traditional Chinese medicine ZHOU Zhongying's experience in treating tumors by compounding formulae from syndrome differentiation based on pathomechanism［J］. J Nanjing Univ Tradit Chin Med， 2021，37（5）：765-768.
73. 73.
    WU M H. WU Mianhua's experience of effective prescriptions—Xiaoai Jiedu prescription［J］. Jiangsu J Tradit Chin Med， 2021，53（9）：1-2.
74. 74.
    WANG J， WANG B B， WANG P， et al. The main medicinal components and research progress of Bombyx batryticatus［J］. North Sericulture， 2024，45（1）：6-9.
75. 75.
    TANTAI J C， ZHANG Y， ZHAO H. Heterophyllin B inhibits the adhesion and invasion of ECA-109 human esophageal carcinoma cells by targeting PI3K/Akt/β-catenin signaling［J］. Mol Med Rep， 2016，13（2）：1097-1104.
76. 76.
    CHEN M， HU C， GUO Y， et al. Ophiopogonin B suppresses the metastasis and angiogenesis of A549 cells in vitro and in vivo by inhibiting the EphA2/Akt signaling pathway［J］. Oncol Rep， 2018，40（3）：1339-1347.
77. 77.
    WANG C L， ZHANG Y， WEN X D， et al.Ethanol extract of Bayuezha［Akebia trifoliata（Thunb.） Koidz.］ inhibits proliferation and induces apoptosis of H22 liver cancer mice cell via PI3K/Akt signaling pathway［J］. China Arch Tradit Chin Med， 2022，40（9）：73-77.
78. 78.
    XU L L， CHEN H， WU M J， et al. miRNA expression of SMMC-7721 cell induced by Xiaoai Jiedu formula［J］. Chin J Exp Tradit Med Form， 2018，24（7）：89-94.
79. 79.
    PAN J Y， CHENG H B. Clinical efficacy of Xiaoai Jiedu formula combined with FEC chemotherapy on breast cancer patients［J］. Chin J Exp Tradit Med Form， 2019，25（6）：95-100.
80. 80.
    SHEN Z J， LI S Y， XU L X， et al. Xiaoai Jiedu prescription-containing serum enhances lethal effect of NK cells on colon cancer cells［J］. Chin J Exp Tradit Med Form， 2022，28（13）：85-91.
81. 81.
    HAN P. Analysis on assistant medication theory of Professor WANG Xin-lu［J］. Chin Arch Tradit Chin Med， 2010，28（4）：701-702.
82. 82.
    WANG X B， HOU Y， WANG W X， et al. Research progress on the pharmacological effects and mechanism of Tibetan medicine Rhodiola rosea［J］. China Pharm， 2019，30（6）：851-856.
83. 83.
    ZHOU X W， WANG Y， WANG N. Research progress in chemical constituents and pharmacological effects of Akebiae Fructus［J］. Central South Pharm， 2021，19（4）：691-696.
84. 84.
    DAI L L， HOU H A， DOU H H， et al. Clinical study of Yichang Sanjie prescription combined with chemotherapy in treating patients with metastatic colorectal cancer of spleen deficiency with phlegm and blood stasis type［J］. J Oncol Chin Med， 2023，5（4）：33-40.
85. 85.
    ZHANG L， ZHOU J J， GUO Q， et al. Professor HOU Aihua skillfully used the Liujunzi decoction to individualize the treatment of gastric cancer［J］. Hebei J Tradit Chin Med， 2023，45（2）：192-195.
86. 86.
    LIU Z， MI Z T， TAN S， et al. HOU Aihua's experience of differentiating syndromes and prescribing medications for toxic side effects of chemotherapy in cancer treatment［J］. Shanghai J Tradit Chin Med， 2024，58（1）：52-56.
87. 87.
    HE LS， SONG P， ZHAO LH， et al. New strategy of ''syndrome differentiation & targeted therapy''：The historical choice of traditional Chinese medicine from macro to precision［J］. Liaoning J Tradit Chin Med， 2020，47（1）：1-4.
88. 88.
    ZHOU L， LUO J L， TANG C， et al. An experiential effective case of treating adverse reactions of postoperative chemotherapy for ovarian cancer based on state-target differentiation by TONG Xiaolin［J］. Jilin J Chin Med， 2023，43（8）：961-964.
89. 89.
    SUN Y， LIANG W Z. Research progress on chemical constituent， pharmacological effects and clinical application of Fritillaria thunbergii［J］. Special Wild Econom Animal Plant Res， 2022，44（1）：87-92.
90. 90.
    CHEN S Y， LI Y， TAN X Y， et al. Effects and mechanisms of notoginsenoside Ft1 on migration， invasion and apoptosis of cervical carcinoma Siha cells［J］. J Mod Oncol， 2024，32（12）：2154-2160.
91. 91.
    CHENG H B， WANG J Y， LI L， et al. Preliminary construction of the state and target combined differentiation and treatment system for malignant tumors［J］. J Tradit Chin Med， 2023，64（13）：1317-1321.
92. 92.
    LIU W H. Study on the efficancy and mechanism of Xianlian JIedu decoction in inhibiting liver metastasis of colorectal cancer based on tumor micrienvironment［D］. Nanjing ： Nanjing University of Chinese Medicine，2021.
93. 93.
    Guangxi famous TCM doctor HUANG Zhifen's empirical prescription： Jianpi Xiaoji decoction［J］. Guangxi J Tradit Chin Med， 2024，47（2）：78.
94. 94.
    WU Z Z， ZHOU Y L， ZHOU G Q， et al. National famous Chinese medicine doctor professor LING Xiangli analyzed the experience of identifying and treating ovarian cancer［J］.Chin Health Care， 2024，42（6）：159-161.
95. 95.
    XU Q， ZHOU Y L， XUN B X， et al. National famous TCM practitioner JIA Yingjie's experience in treating ovarian cancer based on "removing turbidity and cultivating the root"［J］. J Hunan Univ Chin Med， 2024，44（1）：60-64.
96. 96.
    LIU D F. A study of Professor Piao Bingkui treatment based on patters uniquen identification system of lung cancer［D］. Beijing ： China Academy of Chinese Medical Sciences，2023.
97. 97.
    YI L， TANG W， PAN B， et al. National famous Chinese medicine practitioner PAN Minqiu's experience in the treatment of lung cancer［J］. Hunan J Tradit Chin Med，2022，38（4）：38-41.
98. 98.
    ZHOU H R， HUANG T. Summary of professor HUANG Ting's self-made Liqi Jianpi decoction in treating advanced primary liver cancer［J］. J Zhejiang Chin Med Univ， 2022，46（4）：428-432.
99. 99.
    GUO Q， LIU W， HUANG X M， et al. Professor HOU Aihua's postoperative experience in the treatment of lung cancer with Kangfei Sanjie formula［J］. Hebei J Tradit Chin Med， 2022，44（6）：1011-1015.
100. 100.
     HUAI B G， YAO P Y， CAI J R， et al. Professor LIU Deshan's experience in treating pain syndrome with Xuchangqing based on the theory of assistant medications［J］. Clin J Chin Med， 2022，14（20）：113-116.
101. 101.
     ZHOU L，BAO T T， LUO J L， et al. A case report of Academician TONG Xiaolin treating pain caused by prostate cancer bone metastasis［J］. Jilin J Chin Med， 2022，42（12）：1449-1452.
102. 102.
     ZHANG C H， LI K Q， GAO W H， et al. Professor ZENG Puhua's treatment based on pattern identification for cancer cachexia based on "toxins activation and state-target simultaneous modulation" theory［J］. J Hunan Univ Chin Med， 2023，43（12）：2313-2317.
103. 103.
     QI Y J， LI K Q， ZENG P H. Based on the idea of ''seven emotions of depressed poison-cancer poison transformation''， the idea of ''state target discrimination'' for breast cancer was constructed［J］. Asia-Pacific Tradit Med， 2023，19（6）：112-116.
104. 104.
     WANG S S. The study on Professor ZHOU Zhongying's clinic experinence in the treatment of primary lung cancer the experimebtal study on antitumor effect of Yifeijiedu decoction［D］. Nanjing ： Nanjing University of Chinese Medicine， 2017.